The positive results from the Phase 2 trial of Pemvidutide, showing significant weight loss, are likely to boost investor confidence in Altimmune. The company's financial stability, with a cash runway into 2026, supports its ability to reach future milestones, including Phase 3 trials. This positions Altimmune well for potential growth, making the short-term impact on its stock price likely positive.